10 Takeover Targets to Watch This Fall
Pace of Biopharma M&A Slows from First Half Stampede of Deals
Vertex’s David Altshuler Humanizes Drug Discovery
Lessons from Vertex’s Small Molecule Drug Development Program for Cystic Fibrosis
Bispecific Playgrounds? No, Factory Floors
Developers Prepare for Future Biologics Work by Exploring a Multitude of Antibody Formats
In the mAb Race, Don’t Stumble at Characterization
Researchers Adapt Existing Techniques to Deal with Challenging New Monoclonal Antibodies
For full access to this article login to GEN Select now.
Predicting Drug Toxicity in Humans
- Adverse drug reactions (ADRs) are the fourth leading cause of death worldwide. In the U.S. alone, 2.2 million serious ADRs are reported annually in the hospitalized population, with over 100,000 deaths. Models that better predict a drug’s efficacy and a drug’s toxicity cost-effectively are the need of the ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.